Roche (NASDAQOTH: RHHBY )
rarely does expensive early stage deals, relying instead upon its deep
proprietary pipeline of oncology drug candidates. So when the company
commits itself to $725 million upfront and $1 billion more in milestones
(to say nothing of the hundreds of millions that will be required for
clinical trials) for a new cancer drug approach, investors would do well
to pay attention. When that new approach concerns breast cancer, an
area where Roche is particularly strong, it's all the more interesting.
Continue here:
Roche Holding Ltd Is Betting Billions on This New Blockbuster
No comments:
Post a Comment